Malignant Tumor clinical trials at UCLA

1 research study open to eligible people

Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
open to eligible people ages 12 years and up
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Los Angeles, California and other locations

Our lead scientists for Malignant Tumor research studies include Noah Federman, MD.

Last updated: March 12, 2024

Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)